The APOBEC3 family: a narrative review of an alternative therapeutic agent for hepatitis B virus-induced hepatocellular carcinoma
Authors:
- Jing MiaoJMJing Miao
- Meng ZhangMZMeng Zhang
- En RenEREn Ren
- Lan-Tian HuangLHLan-Tian Huang
- Kai-Feng HeKHKai-Feng He
- Zhi-Gang GaoZGZhi-Gang Gao
Open Access
- 1 February 2026
- journal article
- review article
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 17 (1) , 30
Abstract
Background and Objective: Hepatocellular carcinoma (HCC) ranks among the most prevalent cancers globally, representing a significant challenge to healthcare systems around the globe. Hepatitis B virus (HBV) infection is the primary causal factor for HCC, alongside various other risk elements. Timely intervention for HBV holds the potential to effectively prevent the onset of HCC. However, standard first-line treatments, such as nucleos(t)ide analogues and interferon-α (IFN-α), seldom result in complete HBV eradication. Additionally, emerging approaches such as gene editing are still immature and entail certain risks. This review aimed to characterize the roles of the APOBEC3 (A3) family in HBV-associated disease, particularly HCC, with the goal of presenting a novel perspective for its management. Methods: A literature search of the relevant databases was conducted, with a focus on recent and key publications in the English language. The search strategy included terms related to APOBEC3, HBV, and HCC. Key Content and Findings: The APOBEC3 (A3) protein family, whose members function as DNA cytidine deaminases, exhibits the capacity to impede viruses and modulate a variety of tumor types. Members of the A3 family exert a dual effect in HBV-induced HCC (HBV-HCC), both demonstrating antiviral efficacy and potentially contributing to carcinogenic mutations that promote cancer initiation and advancement. Conclusions: The paradoxical nature of the A3 protein family—possessing both antiviral properties and carcinogenic potential—highlights its complex role in HBV-HCC. Understanding these regulatory mechanisms may provide novel insights into developing innovative management strategies for HBV-HCC.Keywords
This publication has 108 references indexed in Scilit:
- Interferon‐inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication†Hepatology, 2006
- Anti-viral protein APOBEC3G is induced by interferon-α stimulation in human hepatocytesBiochemical and Biophysical Research Communications, 2006
- Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA LevelJAMA, 2006
- Inhibition of hepatitis B virus replication by APOBEC3Gin vitroandin vivoWorld Journal of Gastroenterology, 2006
- APOBEC‐mediated interference with hepadnavirus production†Hepatology, 2005
- Tumor necrosis factor-α-induced protein 1 and immunity to hepatitis B virusWorld Journal of Gastroenterology, 2005
- Antiviral Function of APOBEC3G Can Be Dissociated from Cytidine Deaminase ActivityCurrent Biology, 2005
- Unedited inhibition of HBV replication by APOBEC3GJournal of Hepatology, 2004
- Inhibition of Hepatitis B Virus Replication by APOBEC3GScience, 2004
- An Anthropoid-Specific Locus of Orphan C to U RNA-Editing Enzymes on Chromosome 22Genomics, 2002